YUKI GOSEI KOGYO CO.,LTD. Logo

YUKI GOSEI KOGYO CO.,LTD.

Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.

4531 | T

Overview

Corporate Details

ISIN(s):
JP3946400003
LEI:
Country:
Japan
Address:
中央区日本橋人形町三丁目10番4号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuki Gosei Kogyo Co., Ltd. is a chemical manufacturing company established in 1947. Specializing in the field of organic synthesis, the company engages in the research, development, manufacturing, and marketing of fine chemical products. Its core product portfolio includes amino acids (such as Glycine), pharmaceuticals, active pharmaceutical ingredients (APIs), and various chemical intermediates. Utilizing its unique and proprietary technologies, Yuki Gosei Kogyo serves both Japanese and international markets, providing high-quality products for various industrial applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:35
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 02:32
Interim Report
半期報告書-第106期(2025/04/01-2026/03/31)
Japanese 184.9 KB
2025-06-24 04:13
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-19 06:08
Governance Information
内部統制報告書-第105期(2024/04/01-2025/03/31)
Japanese 23.0 KB
2025-06-19 06:07
Registration Form
確認書
Japanese 8.8 KB
2025-06-19 06:05
Annual Report
有価証券報告書-第105期(2024/04/01-2025/03/31)
Japanese 724.5 KB
2025-01-08 02:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.8 KB
2024-12-04 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.8 KB
2024-11-13 02:17
Interim Report
確認書
Japanese 8.8 KB
2024-11-13 02:15
Interim Report
半期報告書-第105期(2024/04/01-2025/03/31)
Japanese 188.9 KB
2024-11-06 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.3 KB
2024-10-03 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2024-09-04 03:21
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2024-08-06 04:12
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-06-25 02:36
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB

Automate Your Workflow. Get a real-time feed of all YUKI GOSEI KOGYO CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUKI GOSEI KOGYO CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUKI GOSEI KOGYO CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.